A prospective Randomised, open label, blinded endpoint (PROBE) study to Evaluate DUAL antithrombotic therapy with dabigatran etexilate (110mg and 150mg b.i.d.) plus clopidogrel or ticagrelor vs. triple therapy strategy with warfarin (INR 2.0 - 3.0) plus clopidogrel or ticagrelor and aspirin in patients with non valvular atrial fibrillation (NVAF) that have undergone a percutaneous coronary intervention (PCI) with stenting - RE-DUAL PCI

Boehringer Ingelheim0 个研究点目标入组 30 人开始时间: 待定最近更新: 2024年4月23日

适应症

试验速览

暂无简介。

•- Male or female patients aged ><=18 years;- Patients with Non Valvular Atrial Fibrillation;- Patient presenting with:;An ACS (STEMI, NonSTEMI [NSTEMI] or unstable angina [UA]) that was successfully treated by PCI and stenting (either Bare Metal Stent or Drug Eluting Stent);Or;Stable Coronary Artery Disease with at least one lesion eligible for PCI that was successfully treated by elective PCI and stenting (either BMS or DES) ;- The patient must be able to give informed consent in accordance with International Conference on Harmonisation Good Clinical Practice guidelines and local legislation and/or regulations.

•- Patients with a mechanical or biological heart valve prosthesis;- Cardiogenic shock during current hospitalisation;- Stroke within 1 month prior to screening visit;- Patients who have had major surgery within the month prior to screening;- Gastrointestinal haemorrhage within one month prior to screening, unless, in the opinion of the Investigator, the cause has been permanently eliminated;- Major bleeding episode including life-threatening bleeding episode in one month prior to screening visit;- Anaemia (haemoglobin <=10g/dL) or thrombocytopenia including heparin-induced thrombocytopenia (platelet count <=100 x 109/L) at screening;- Severe renal impairment (estimated CrCl calculated by Cockcroft-Gault equation) <=30mL/min at screening;- Active liver disease

发起方